The global market for NDDS in cancer therapy was valued at USD 3,655.3 million in 2013 and is expected to reach USD 15,984.2 million in 2020, growing at a CAGR of 23.7% during the forecast period from 2014 to 2020.
In January 2015, ownership of Coldstream was transferred to Piramal Enterprises, Ltd., an integrated, global contract services provider. As part of becoming a Piramal-owned organization, Coldstream now has access to the financial resources required to expand its facilities in Lexington, KY to continue to meet the needs of its customers.
We offer fully integrated analytical, formulation development, and pharmaceutical manufacturing services. Staff members have provided a wide range of formulations, testing, and GMP drug product production for a broad spectrum of clients. We are registered with the FDA and the Commonwealth of Kentucky Board of Pharmacy for the manufacturing of pharmaceutical products.
Copyright 2014 | Designed with [fa icon="heart"] by HubSpot